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Abstract  40 
  41 
Hemophilia A (HA) is a rare bleeding disorder caused by deficiency/dysfunction of the FVIII protein. 42 
As current therapies based on frequent FVIII infusions are not a definitive cure, long-term expression 43 
of FVIII in endothelial cells through lentiviral vector (LV)-mediated gene transfer holds the promise 44 
of a one-time treatment. Thus, here we sought to determine whether LV-corrected blood outgrowth 45 
endothelial cells (BOECs) implanted through a prevascularized medical device (Cell Pouch™) would 46 
rescue the bleeding phenotype of HA mice. To this end, BOECs from HA patients and healthy donors 47 
were isolated, expanded and transduced with an LV carrying FVIII driven by an endothelial-specific 48 
promoter employing GMP-like procedures. FVIII-corrected HA-BOECs were either directly 49 
transplanted into the peritoneal cavity or injected into a Cell Pouch™ implanted subcutaneously in 50 
NSG-HA mice. In both cases, FVIII secretion sufficient to improve the mouse bleeding phenotype. 51 
Indeed, FVIII-corrected HA-BOECs reached a relatively short-term clinically relevant engraftment 52 
being detected up to 16 weeks after transplantation, and their genomic integration profile did not 53 
show enrichment for oncogenes, confirming the process safety. Overall, this is the first pre-clinical 54 
study showing the safety and feasibility of transplantation of GMP-like produced LV-corrected 55 
BOECs within an implantable device for the long-term treatment of HA. 56 











Hemophilia A (HA) is an X-linked disorder caused by mutations in the F8 gene.1,2 These mutations 59 
result in deficiency or reduced activity of the coagulation factor VIII (FVIII), leading to a lifelong 60 
bleeding tendency, whose clinical severity is proportional to FVIII reduction.1 Although the current 61 
standard of care is to infuse intravenously HA patients with clotting factor concentrates, the short 62 
half-life of FVIII requires frequent and multiple infusions, with a negative impact on the patient’s 63 
quality of life (QoL). New generation of standard rFVIII was obtained by refinements of the 64 
recombinant protein through the optimization of relevant post-translational modifications like 65 
glycosylation, that improves the stability of the mature FVIII protein,3 or the introduction of a 66 
covalent link between the FVIII heavy and light chains, preserving FVIII from premature degradation 67 
and conferring a higher binding affinity to VWF  with  a reduction of the needed injection dose.4–6 68 
Other new bioengineered molecules were developed with higher extended plasma half-life (EPHL) 7 69 
and improved pharmacokinetics by the fusion of rFVIII with the Fc portion of immunoglobulin8 or 70 
by the conjugation with polyethylene glycol (PEGylation).9  71 
However, several issues are still to be solved as the recurrent intravenous (iv) route of administration 72 
and the inhibitor development, common in 20-40% of patients with the severe form,10 worsen the 73 
clinical outcome, making the treatment ineffective.11,12 Therefore, a new clinical approach emerged 74 
more recently, i.e. emicizumab, to overcome the difficulties of iv delivery and to improve and prolong 75 
the effectiveness of the therapy in all patients, regardless of the inhibitor presence or absence.13,14 76 
However, bleeding events can still occur after trauma requiring the use of additional hemostatic 77 
agents, according to the patients’ inhibitor status.15,16 78 
This has led researchers to explore innovative cell and gene therapy strategies that may ensure 79 
continuous endogenous FVIII expression with only a one-time treatment. Another good reason for 80 
choosing gene therapy over traditional approaches is that HA is a monogenic disease i.e., entirely 81 
ascribable to the lack of one protein, FVIII and that a small increase in FVIII plasma levels is enough 82 










Given the growing number of cell and gene therapy approaches being developed, it is becoming 84 
increasingly important to identify the most suitable cell target. Even though F8 mRNA is expressed 85 
in different human and mouse organs, such as liver, spleen, lymph nodes, kidney,17–20 and in 86 
hematopoietic cells,21,22 transplantation studies in hemophilic animal models have shown FVIII 87 
expression to be mainly localized in liver sinusoidal endothelial cells (LSECs),23–25 making these cells 88 
attractive targets for HA gene therapy. This is also supported by the fact that endothelial cells (ECs) 89 
secrete FVIII and can act as tolerogenic cells.26,27  90 
Over the years, several gene therapy approaches for HA have been attempted using adeno-associated 91 
virus (AAV) vectors to induce FVIII expression in the desired cell type. Despite the encouraging 92 
preliminary results obtained in few ongoing clinical trials testing the efficacy of AAV-mediated 93 
hepatocyte-targeted FVIII expression in HA patients,28–30 some medical issues still need to be 94 
addressed, such as the use of these vectors in patients with pre-existing immunity to AAV or with 95 
FVIII inhibitors. As AAV vectors do not actively integrate into the host cell genome, they are lost 96 
upon cell division during liver growth or in case of liver disease, thus potentially limiting their use in 97 
pediatric patients and questioning their life-long maintenance. Therefore, lentiviral vectors (LVs) 98 
could represent a viable approach able to overcome some AAV limitations. Moreover, several studies 99 
have demonstrated, by the use of endothelial specific promoters, specific expression of human FVIII 100 
in LSECs.23–25,31 Recently, we have shown that induced pluripotent stem cells (iPSCs) derived from 101 
CD34+ HA cells can be differentiated into ECs and genetically corrected by LV to express the FVIII 102 
transgene, deleted of the B domain (BDD), driven by the endothelial specific vascular endothelial 103 
cadherin (VEC) promoter. After transplanting these cells into the liver of monocrotaline-conditioned 104 
NOD-scid IL2Rgnull HA (NSG-HA) mice, we were able to correct the bleeding phenotype of these 105 
mice and maintain a stable FVIII activity over time.32 Moreover, BDD-FVIII-transduced ECs 106 
encapsulated in microcarrier beads have been shown to survive for a prolonged time in the peritoneal 107 










Several studies have focused on defining different cell sources and matrices to transplant FVIII-109 
expressing ECs.33–35 A readily available EC source is represented by patient-derived blood outgrowth 110 
endothelial cells (BOECs).36 BOECs are isolated from adult peripheral blood37  and can be fully 111 
differentiated into mature ECs. They promote neovascularization in vivo when transplanted into 112 
immunodeficient mice38 or when cultured on three-dimensional biodegradable vascular scaffolds.39–113 
41 In addition, they can be considered a valuable source of cells to understand EC biology and model 114 
disease and can be used in regenerative medicine due to their ability to promote neovascularization, 115 
thus representing an optimal candidate for HA cell and gene therapy. Indeed, BOECs transplanted in 116 
NSG-HA mice after gene modification for FVIII expression were able to partially rescue the 117 
hemorrhagic phenotype of these mice.36,42 Moreover, autologous transplantation of FVIII-expressing 118 
BOEC cell-sheet allowed long-term phenotypic correction and survival of transplanted cells.35 119 
Noteworthy, BOECs can promote neovascularization in vivo in combination with synthetic or natural 120 
materials.38  121 
A combination of LV-corrected BOECs with a medical device is classified by the European Union 122 
as a combined gene therapy medicinal product (GTMP).43 The mandatory non-clinical study scheme 123 
prior to the first administration of a cell-based GTMP to human subjects includes the comprehensive 124 
characterization of the transduced cells and the evaluation of the medical device contribution.44 125 
Moreover, the proof-of-concept pharmacodynamics along with the molecular mechanism of action 126 
must be identified in preclinical models in vivo and/or in vitro. These studies are deemed essential to 127 
determine the GMP cell dose to be used in clinical trials.45  128 
Here, we show extensive characterization of LV-transduced BOECs isolated from healthy donors or 129 
HA patients for FVIII production in vivo. These cells were transplanted in a small scalable, 130 
implantable, and prevascularized medical device, namely Cell Pouch™ (Sernova Corp.), previously 131 
developed for diabetes treatment.46  132 
Our findings, showing that Cell Pouch-transplanted LV-corrected HA-BOECs are capable of 133 










Results  135 
Characterization of BOECs isolated from HA patients or healthy subjects and LV-mediated 136 
FVIII gene transfer  137 
Upon isolation and expansion in culture medium, both BOECs from healthy donors and HA patients 138 
showed the classical endothelial cobblestone-like morphology (Figure 1A). Of note, despite being all 139 
isolated from severe HA patients, HA BOECs gave rise to many colonies (Figure S1A) and there was 140 
not a significant difference in the number of isolated colonies between healthy donors and HA patients 141 
(Figure S1B). For transgene expression, isolated cells were transduced with a lentiviral vector (LV) 142 
carrying the BDD form of FVIII driven by the vascular endothelial cadherin promoter (LV-143 
VEC.hBDD-FVIII) or with an LV carrying the green fluorescent protein under the control of the same 144 
promoter (LV-VEC.GFP), both at an MOI of 20. FACS analysis showed 98±1% GFP+ cells after 145 
transduction (Figure S1C), indicating excellent transduction efficiency. The number of integrated LV 146 
copies/cell was ~6 and ~3 for LV-VEC.GFP and LV-VEC.hBDD-FVIII-transduced cells, 147 
respectively (Figure S2A). Thus, this protocol ensures a very high transduction efficiency while 148 
maintaining a safe number of integrated LV copies/cell.47,48  149 
We next assessed the endothelial phenotype and functionality of transduced vs non-transduced 150 
healthy or HA BOECs. As shown in Figure 1B, all cells expressed the classical endothelial markers 151 
(e.g., PECAM1, KDR, TEK, CDH5, and VWF) as well as other genes specific to blood endothelial 152 
cells (BECs)49,50 (Figure 1C). The endothelial phenotype of healthy and HA BOECs was further 153 
verified at the protein level (Figure 1D and E, respectively), while the hematopoietic phenotype was 154 
ruled out upon CD34 and CD45 staining, which resulted negative (Figure 1D and E).  155 
The endothelial functionality of the transduced cells was confirmed by their ability to form tubule 156 
networks upon Matrigel cell culture (Figure 1F). F8 mRNA expression was measured in transduced 157 
BOECs by RT-PCR (Figure 1G), while FVIII protein expression levels were detected by flow 158 










(Figure 1J). Interestingly in healthy BOECs we detected low levels of FVIII (Figure 1H and 1J). This 160 
is in accordance with previous works where FVIII in healthy BOECs was barely observed. 42,51,52 161 
When cell supernatants were subjected to activated partial thromboplastin time (aPTT) assay, we 162 
noticed a consistent shortening in LV-VEC.hBDD-FVIII-transduced BOECs (69± 3.5 sec for 163 
transduced healthy BOECs, 66± 4 sec for transduced HA BOECs) compared to non-transduced cells 164 
(80± 2.8 sec for healthy BOECs, 84± 2.8 sec for HA BOECs) (Figure S2B), in good agreement with 165 
the amount of secreted FVIII (35.9± 2.3 ng/ml for LV-VEC.hBDD-FVIII healthy BOECs, 4.5± 1.3 166 
ng/ml for non-transduced healthy BOECs; 54± 7.5 ng/ml for LV-VEC.hBDD-FVIII HA BOECs, 167 
0.15± 2.5 ng/ml for non-transduced HA BOECs) (Figure S2C).  168 
To further evaluate the safety of LV transduction, healthy BOECs were transduced with different 169 
MOIs (MOI 10, 20, 50, 100), and HIV-1 p24 expression on cell supernatant was assessed. As shown 170 
in Figure S2C, all LV-transduced BOEC supernatants were negative for HIV-1 p24 at any of the 171 
MOIs tested 10 days after transduction, suggesting the reliability of our protocol. HIV-1 p24 on 172 
supernatant of HA BOECs transduced with an MOI of 20 showed comparable results (Figure S2D).  173 
Secretion of the FVIII gene product by LV-transduced HA or healthy BOECs in NSG-HA mice 174 
Since healthy and HA BOECs were both able to secrete FVIII in vitro, we evaluated their ability to 175 
survive and secrete FVIII in NSG-HA mice following intraperitoneal (i.p.) injection in association 176 
with Cytodex® 3 microcarrier beads. Following injection, FVIII-transduced GFP+ healthy BOECs 177 
were able to partially restore FVIII activity, which reached a peak of approximately 10% at 4 weeks 178 
post injection (pi) and persisted above 5% for up to 10 weeks pi (Figure 2A). As expected, LV-179 
VEC.GFP BOEC controls showed only basal FVIII secretion, which only lasted for 4 weeks. 180 
Importantly, mice receiving FVIII-transduced HA BOECs revealed sustained therapeutic FVIII 181 
activity (up to 10%) for up to 13 weeks pi, which persisted at a level < 5% throughout the 18 following 182 
weeks (Figure 2A). Blood loss assays, run between 7 and 10 weeks p.i. of FVIII-transduced GFP+ 183 
HA BOECs, demonstrated partial hemostasis restoration (Figure 2B) accompanied by detectable 184 










experimental group were killed, and beads were recovered from the abdominal cavity. IF staining 186 
was performed on the recovered beads using an anti-GFP antibody that would detect the transplanted 187 
cells, which were previously transduced with both LV-VEC.GFP and LV-VEC.FVIII. Therefore, the 188 
presence of GFP+ cells confirm that they are still associated with the beads and that they maintained 189 
an endothelial phenotype, as shown by the co-staining with CD31 (Figure 2D).  190 
Large scale expansion of FVIII-transduced cells 191 
With the aim to translate this approach into the clinic, we developed a protocol that would allow us 192 
to obtain a large amount of transduced HA BOECs for our in vivo experiments. LV-VEC.hBDD-193 
FVIII-transduced HA BOECs from four patients were large-scale expanded to reach 108 cells, frozen 194 
and sent to the partners in accordance with GMP-like procedures. Upon arrival, cells were re-cultured 195 
by simulating a centralized cell production process with long-term cryopreservation. After large-scale 196 
expansion and cryopreservation, upon thawing and reseeding, all cells showed normal cobblestone-197 
like morphology (Figure 3A). Even though their size was slightly enlarged, no significant changes in 198 
their doubling time, cell density, and length of time required for expansion were noticed (Figure 3B). 199 
In addition to maintaining expression of the classical endothelial markers (CD31, KDR, Tie-2, VEC), 200 
expanded BOECs became CD34+, a transmembrane phosphoglycoprotein involved in cell adhesion,53 201 
while they retained the classical CD45- phenotype (Figure 3C).  202 
Functionally, FVIII-transduced cells preserved their tubulogenesis activity (Figure 3D) and led to 203 
partial restoration of FVIII activity once transferred into NSG-HA mice (Figure 3E), similar to the 204 
kinetics of non-expanded BOECs. Thus, LV-VEC.hBDD-FVIII HA BOECs maintain their ability to 205 
secrete FVIII at therapeutic levels even after large-scale expansion. 206 
Tissue matrix development and safety of LV-VEC.hBDD-FVIII-transduced BOECs within a 207 
Cell Pouch™ implanted in NSG-HA mice 208 
The Cell Pouch™ is a medical implantation device specifically designed to enable the development 209 
of a vascularized tissue matrix environment that ensures long-term survival and function of 210 










within the Cell Pouch™ implanted in NSG-HA mice. For this purpose, 4-week implanted Cell 212 
Pouches™ were transplanted with one of three doses (2×, 5× or 10×106) of LV-VEC.hBDD-FVIII 213 
HA BOECs isolated from two separate HA donors. The Cell Pouches™ transplanted with BOECs 214 
were explanted at 4, 8, or 12 weeks, and a gross pathological assessment was performed. HA BOECs 215 
were safe across doses and time points with no visible tumors observed (n = 60 total; HA1 n = 37; 216 
HA2, n = 23) (data not shown). 217 
Overall, the tissue matrix developed within the Cell Pouch™ internal chamber and transplant area 218 
was viable among all groups according to time, dose, and cell lot, with no apparent signs of 219 
inflammation, hemorrhage, fibrosis, or necrosis (Figure 4A and Table S1). The center of the 220 
transplanted chamber area showed mild to moderate collagen deposition without any difference due 221 
to donor lot, time, or dose. Within the area of pre-vascularization, there was comparatively an increase 222 
in established collagen, indicating that the Cell Pouch™ promoted, over time, the development of a 223 
natural scaffold to provide strength and structure to the environment irrespective of the transplant. 224 
Regarding tissue vascularization, there was moderate neovascularization of the central, transplanted 225 
tissue of the Cell Pouch™ that was present in both donor lots, as well as the controls, along with 226 
evidence of established vessel growth, indicating that the tissue development within this area included 227 
new blood vessel formation (Figure 4B). Established vessels within the central, transplanted zone 228 
appeared to be more prominent and donor-dependent at the latest time points (Figure 4A). 229 
Transduced HA BOECs improve the bleeding phenotype and cell survival in mice after 230 
transplantation into the vascularized Cell Pouch™ 231 
The therapeutic efficacy of LV-VEC.hBDD-FVIII HA BOECs transplanted into the Cell Pouch™ 232 
was evaluated by performing a tail bleeding assay on NSG-HA mice four months after the cell 233 
transfer. Remarkably, we noticed a significantly improved presence of clotting as judged by a 234 
reduction in blood volume recovered in animals transplanted with 20×106 LV-VEC.hBDD-FVIII HA 235 
BOECs compared to non-transplanted mice (Figure 5A). Notably, this was not significantly different 236 









achieved in the transplanted HA mice. Relatively long-term cell survival (4 months post-transplant) 238 
was confirmed by co-staining with anti-HLA-ABC and anti-vWF antibodies as well as by the 239 
formation of blood vessels within the transplanted area (Figure 5B, 5C and Table S2).  240 
Overall, these data indicate that corrected HA BOECs are able to engraft and persist for prolonged 241 
periods of time within the tissue matrix supported by the Cell Pouch™ and secret enough FVIII to 242 
correct the hemophilia phenotype of the implanted NSG-HA mice. 243 
Complex composition of BOEC clonal populations 244 
Sonication Linker Mediated PCR was performed on 53 samples of genomic DNA extracted from LV-245 
transduced BOECs derived from 3 healthy donors (D45, D2, and D3) and 3 HA patients (pHA1, pA, 246 
and pC), collected at different expansion passages or procedure time points. By grouping the samples 247 
according to the BOEC source (i.e., healthy donors or HA patients) and the type of vector used (i.e., 248 
LV-VEC.hBDD-FVIII or LV-VEC.GFP), we obtained 4 main groups: HA.FVIII; HA.GFP; 249 
Healthy.FVIII; Healthy.GFP. Overall, we retrieved 142,349 integration sites (IS) (HA.FVIII: 28,069; 250 
HA.GFP: 106,554; Healthy.FVIII: 5,864; Healthy.GFP: 1,862.) (Table S3). We compared the 251 
distribution of IS of the 4 groups along the whole human genome and with respect to gene 252 
transcription start site (TSS). The profile of LV integrations was similar for all the groups and 253 
confirmed the marked tendency of the LV to integrate within gene bodies, without bias for promoter 254 
regions (Figure 6A-B), in line with previously published results.54–57 Following enrichment analysis 255 
of genomic position and gene annotations, none of the ontological gene classes showed cancer or 256 
tumor suppressor gene enrichment (Table S4).  257 
Common Insertion Site (CIS) analysis showed few highly targeted genes in all datasets (e.g., 258 
NPLOC4, PACS1, and MROH1) (Table S5). The quantification of IS Abundance showed only a few 259 
clones with abundance > 10% in LV-VEC.hBDD-FVIII-transduced BOECs from pA and pHA1 260 
(Figure 7). Only 2 IS were retrieved from D45 cells transduced at an MOI of 30, thus resulting in 261 
both to be 50% abundant. One clone with an IS in the GNL3 gene, which may interact with p53 and 262 










but only at a single time point (P11-UK). To address the clonality of transduced BOECs, we analyzed 264 
the diversity of the clonal population through Shannon diversity index. The highest Shannon diversity 265 
index, between 9 and 11, was observed in BOECs from pHA1 and pA, transduced with the VEC.GFP 266 
vector. All the other BOECs showed a Shannon diversity index between 4 and 8, which remained 267 
constant throughout the various cell passages. A lower diversity index directly correlated with a lower 268 
number of IS, in particular for the HA Beads and Cell Pouch™ samples at different time points 269 
(Figure 8A). To better understand if, especially in the Cell Pouch™ samples, the clonal diversity was 270 
reduced, we compared the H Index between samples grouped by type (Expansion, HA Beads, Cell 271 
Pouch™ and LV used (VEC-FVIII, VEC-GFP) (Figure 8B). IS analysis revealed a high level 272 
polyclonality of LV-transduced BOECs, with no significant difference between the FVIII- and GFP-273 
transduced samples. The clonal composition heterogeneity of FVIII-transduced samples remained 274 
constant over time in vitro and in vivo. Finally, Cell Pouch™ samples had a significant lower H index 275 
when compared to BOECs in expansion. 276 
 277 
DISCUSSION  278 
Although the current therapy for HA involves the administration of plasma-derived or recombinant 279 
FVIII, there is to date no definitive cure for this inherited bleeding disorder. While several ongoing 280 
phase 1-3 clinical trials assessing the feasibility and safety of AAV-mediated hepatocyte-directed HA 281 
gene therapy have been able to achieve therapeutic FVIII plasma levels,58–61 further experiments are 282 
in progress to assess the long-term stability of transgene expression. In this regard, the fact that AAV 283 
vectors do not actively integrate into the host cell genome and, thus, can be lost upon cell division 284 
during liver growth or liver disease questions their life-long maintenance besides limiting their 285 
potential use in pediatric patients.  286 
A promising alternative approach is represented by a combination of cell and gene therapy, which 287 
would however require the identification of a suitable cell type able to effectively secrete FVIII while 288 










acknowledged that the liver is the main organ producing FVIII, where LSECs appear to be the main 290 
source of FVIII62–64 and can play a tolerogenic role. In addition, because of the important role of the 291 
interaction between FVIII and vWF in the stability and activity of FVIII, LSECs may represent the 292 
most suitable target for cell and gene therapy-based strategies aimed to correct the HA phenotype.65 293 
Unfortunately, LSEC are not easy to obtain and maintain in vitro, therefore, in this study we explored 294 
the feasibility of using gene-corrected autologous BOECs, more manageable and previously shown 295 
to be able to secrete FVIII in vivo.66 Here we show that BOECs isolated from both healthy and HA 296 
donors can be efficiently cultured, transduced, expanded, and used to correct the bleeding phenotype 297 
of HA mice. In this regard, it is important to point out that the large number of corrected cells we 298 
obtained allowed us to reach more quickly FVIII therapeutic concentrations, thus reducing the risk of 299 
cell senescence.  300 
The current protocols for BOEC isolation are based on the culture of mononuclear cells (MNCs) from 301 
peripheral or umbilical cord blood on collagen-coated cell culture vessels in endothelial specific 302 
medium.67 The fact that MNCs can be isolated directly through density gradient centrifugation of 303 
blood makes these cells a safe cell source for hemophilic patients. Normally, BOECs colonies arise 304 
after 2-4 weeks of culture, and the colonies are very rare since their number in the normal peripheral 305 
blood is quite low.67 However, here we show that, under GMP-compliant conditions and using a 306 
chemically defined medium, it is possible to isolate BOECs from both healthy donors and HA patients 307 
with high efficiency and rapidly grow them to the desired amount to prevent the risk of cellular 308 
senescence once transplanted in mice.  309 
In addition to being more easily obtainable, BOECs are fully differentiated ECs with a mature 310 
endothelial phenotype. Indeed, these cells originate from bone marrow-derived progenitors 311 
circulating in the blood or residing in the endothelium, which can be differentiated into BOECs in 312 
vitro.68 Thus, the observation that the expanded pools of BOECs from healthy donors or HA patients 313 
retained the expression of endothelial markers and were able to form vessels indicates that our GMP-314 










shown.68  Moreover, the healthy BOECs showed low FVIII expression, as demonstrated by IF 316 
staining and FACS analysis, in agreement with the low FVIII secretion found in the cell supernatant. 317 
This is similar to what has been shown by previous studies in which  healthy BOECs isolated from 318 
both canine and human donors displayed low FVIII expression.42,51,52 Indeed, FVIII expression 319 
heterogeneity among different endothelial subpopulations has been reported, with the sinusoidal 320 
endothelial cells shown as the main FVIII-secreting cells.69Another important aspect of this study is 321 
that we efficiently transduced BOECs with an LV carrying a functional BDD form of FVIII driven 322 
by the endothelial-specific promoter VEC. The efficiency and tissue specificity of FVIII transcription 323 
under the control of this promoter has been previously demonstrated in gene therapy approaches 324 
showing the restriction of FVIII expression in the desired cell type70 and in cell therapy by secretion 325 
of FVIII after genetic correction in target cells.32 Here, we show that LV-corrected HA BOECs 326 
transplanted in association with Cytodex® 3 microcarrier beads into the peritoneum of NSG-HA mice 327 
rescues the hemophilic phenotype of these animals for up to 18 weeks, achieving 9% FVIII activity.  328 
Importantly, we reached therapeutic levels of secreted FVIII through LV-VEC.hBDD-FVIII HA 329 
BOECs injection into a prevascularized Cell Pouch™ device transplanted into a preclinical murine 330 
model of severe HA. Notably, the correction of the bleeding phenotype by using LV-VEC.hBDD-331 
FVIII HA BOECs injected into the peritoneum lasted up to 13 weeks and then slowly decreased. 332 
After 18 weeks FVIII activity was almost absent probably due to the death of BOECs. 333 
Despite the encouraging results presented in this proof-of-concept study in a pre-clinical setting, there 334 
still remain several important issues that need to be addressed before our approach can be brought 335 
into the clinic. For instance, it will be imperative to characterize the cells within the Cell Pouch™ in 336 
terms of cell markers, longevity, and proliferation/senescence status. It will also be important to assess 337 
if we can increase the expression levels of FVIII using different EC-specific promoters, and if that 338 
would translate into augmented FVIII secretion and functionality ex-vivo.  339 
Overall, our findings indicate that cell transfer into a medical device is a suitable solution for cell 340 










an excellent rate and escape from the immune response of the transplanted organism, all the while 342 
allowing nutrient exchange and therapeutic protein secretion. Congruently, the safety and efficacy of 343 
the Cell Pouch™ for the transplantation of mouse pancreatic islets has been previously shown to 344 
provide insulin independence in diabetic animals in preclinical studies of type 1 diabetes mellitus.46,71 345 
Furthermore, a phase I/II clinical trial is ongoing for the treatment of T1DM patients whose result 346 
may support the potential application of this device to other diseases for cell therapy approaches, such 347 
as HA.72  348 
The Cell Pouch™ is a biocompatible, safe, implantable device that forms an internal vascularized 349 
tissue matrix supporting the transplanted cells. When we analyzed the Cell Pouch™ injected with 350 
LV-VEC.hBDD-FVIII HA BOECs after 4 weeks from the cell transfer, we observed the presence of 351 
a viable vascularized tissue matrix supporting the cells, with no evidence of fibrosis-associated 352 
consequences, including inflammation and necrosis, or hemophilia-related hemorrhage episodes. 353 
Moreover, the bleeding assay demonstrated that LV-VEC.FVIII HA BOECs transplanted into the 354 
vascularized subcutaneous Cell Pouch™ were able to correct the clotting function of HA mice. FVIII 355 
secretion and activity measurement would support the data on hemophilic correction and strengthen 356 
our observations. These tests are planned for future studies. 357 
As previously shown in a canine model of HA, BOECs transduced with an LV carrying the canine 358 
FVIII and implanted subcutaneously allowed secretion of therapeutic levels of FVIII up to 15 weeks 359 
in Matrigel scaffolds and up to a year after omental implantation.66 Moreover, BOECs were shown 360 
to form tubule network in vitro when plated on Matrigel73 or on the surface of synthetic vascular 361 
scaffolds74 and to promote neovascularization in vivo when transplanted into immunodeficient mice,38 362 
suggesting that they can be directly involved in vessel formation.  363 
In this context, our data attest the feasibility of a method to correct autologous cells based on a 364 
combined cell and gene therapy approach together with the use of a scaffold (i.e., Cell Pouch™) able 365 
to guarantee long-term cell survival and, in case of need, a re-injection of new therapeutic cells. In 366 










demonstrate the pharmacodynamics proof-of-concept in non-clinical models, which is mandatory 368 
before any GTMP can be used in human clinical trial.44,45  Thus, our next step will be to evaluate the 369 
safety and toxicity of the GTMP in vivo based on these results so as to ensure patient safety and 370 
promote product translation. Examples of required non-clinical studies are the evaluation of the 371 
potential tumorigenicity and biodistribution of the transduced BOECs with or without the medical 372 
device.75 Our molecular analysis of the integration sites in BOECs shows that no enrichment for 373 
oncogenes or expansion of clones with IS in CIS or biases toward gene classes related to cancer genes 374 
occurred. IS analysis suggests a high level of polyclonality of LV-transduced BOECs, with no 375 
statistical difference between the FVIII- and GFP-transduced samples. The heterogeneity of the clonal 376 
composition of the FVIII-transduced samples remained constant over time (between different cell 377 
passages) also when cells were coupled to the micro carrier beads. Furthermore, Cell Pouch™ 378 
samples had a statistically significant lower H index when compared to BOECs in expansion.  379 
The process of BOEC engraftment within the subcutaneous space is novel and complex and further 380 
studies will provide additional insight into the interactions between the developing tissue and the 381 
transplanted cells, elucidating the role played in the kinetics of blood vessel formation and FVIII 382 
secretion within the surrounding tissue.  383 
In this study, we could not evaluate the immune response to the secreted factor because we used 384 
implanted cells in immunodeficient hemophilic mice. Thus, in future studies it will be interesting to 385 
evaluate antibody formation after transplantation of transduced BOECs encapsulated in the Cell 386 
Pouch™ into immunocompetent mice. Finally, while several gene therapy clinical trials for HA are 387 
ongoing, to our knowledge this is the first therapeutic approach that combines the GMP production 388 
of autologous human BOECs with the use of a safe ex-vivo approach based on an implantable 389 
prevascularized device.  390 
In conclusion, our findings suggest that long-term encapsulation and survival of LV-corrected BOECs 391 
by means of an implantable device may prove effective in ameliorating the HA patients’ QoL. The 392 










prevent the need of frequent infusions of FVIII and significantly reduce the morbidity and the 394 
frequency of the bleeding episodes in hemophiliacs. 395 










Material and Methods  397 
BOEC isolation form HA patients and healthy donors 398 
Blood sampling from 4 adult severe HA patients, named pHA1, pA, pC, and pD, was performed at 399 
the hospital A.O.U Città della Salute e della Scienza, Turin, Italy. The blood was shipped at room 400 
temperature to Università del Piemonte Orientale (UPO), Novara, Italy. Blood sampling from adult 401 
severe HA patients was approved by the Ethics Committee “Comitato Etico Interaziendale A.O.U. 402 
Maggiore della Carità” (Protocol 810/CE, Study n. CE 125/17). Human BOECs were isolated as 403 
previously described,67 with the introduction of an earlier cell passaging step seven days after initial 404 
isolation of the peripheral blood mononuclear cells to reduce expansion time and increase the final 405 
cell yield.76 Isolated cells were cultured on CELLCOAT Collagen Type 1-coated tissue culture flasks 406 
(Greiner Bio-One) using MCDB 131 medium (Gibco®, Life Technologies) containing proprietary 407 
supplements. Primary cells from adult healthy donors (named D45, D2, D3) were isolated at Tissue 408 
Engineering and Regenerative Medicine, Würzburg, Germany, under informed consent according to 409 
ethical approval granted by the Institutional Ethics Committee of the University Hospital Würzburg 410 
(approval number 182/10). Cell viability and count were assessed using the Countess II FL 411 
Automated Cell Counter (Thermo Fisher Scientific). 412 
Healthy and HA BOEC transduction  413 
Healthy and HA BOECs were plated at a 104 cells/cm2 density and after 6-8 h transduced with a 414 
lentiviral vector carrying the BDD form of FVIII under the control of the VE-cadherin promoter (LV-415 
VEC.hBDD-FVIII) or with a lentiviral vector carrying the green fluorescent protein under the control 416 
of the same VE-cadherin promoter (LV-VEC.GFP), using a multiplicity of infection (MOI) of 20. 417 
After 14-16 h incubation, fresh medium was added to the cells and, 72 h later, half of the cells were 418 
harvested for subsequent analysis, while the other half was further cultured.  419 










BOECs were isolated and expanded using a GMP-compliant standardized approach between all 422 
partners, including a quality control strategy. The standardized expansion scheme defined within the 423 
project is based on the generation of Master Cell Banks (MCB) and a Working Cell Bank (WCB), 424 
which ensures not only a controllable defined expansion for each patient’s BOECs but also an in-425 
process quality control at defined crucial steps. After isolation and expansion, cells were transduced 426 
with LV lots produced with a GMP-compliant method (TFF, see Supplemental Material section). All 427 
freezing steps were performed using a cryopreservation solution based on compounds that are GMP-428 
compliant free of toxic compounds (e.g., DMSO). The Cell Pouch™ was manufactured under GMP-429 
compliant conditions. All steps were designed and conducted according to European GMP-430 
regulations to ensure that the product would fully comply with the quality requirements of the 431 
European authorities. The main objectives were to provide sets of design and manufacturing protocols 432 
based on current European GMP regulations and to prepare an Investigational Medicinal Product 433 
Dossier (IMPD) for an Investigational Medicinal Product (IMP), composed of therapeutic cells and 434 
an implantable medical device (Cell Pouch™), a so-called combined Advanced Therapeutic 435 
Medicinal Product (combined ATMP). 436 
Insertion site analysis 437 
Integration sites (IS) were retrieved from genomic DNA of LV-transduced BOEC cells by Sonication 438 
Linker Mediated (SLiM)-PCR, an adaptation of a previously described method.77,78 Genomic DNA 439 
(300 ng) was sheared using a Covaris E220 Ultrasonicator (Covaris Inc., Woburn, MA), generating 440 
fragments with a target size of 1000 bp. The fragmented DNA was split into 3 parts to generate 441 
technical replicates and, by using the NEBNext® Ultra™ DNA Library Prep Kit for Illumina® (New 442 
England Biolabs, Ipswich, MA), subjected to end repair, 3’ adenylation, and ligation to linker 443 
cassettes (Integrated DNA Technologies, Skokie, IL) containing a 8-nucleotide sequence barcode 444 
used for sample identification and a 12 random nucleotide sequence necessary for clonal abundance 445 









specific for the lentiviral vector LTR and the linker cassette. The amplification product was then re-447 
amplified with additional 10 PCR cycles using primers specific for the linker cassette and the LTR, 448 
with the latter containing a second barcode in order to adopt a double barcode strategy for sample 449 
identification. The final PCR products were quantified using a KAPA Library Quantification Kit 450 
(Roche, Basil, Switzerland) and pooled in sequencing libraries with equimolar composition, avoiding 451 
repeated barcode pairs. Primers incorporate the adapter sequences required for the Illumina paired 452 
end sequencing technology (Illumina, San Diego, CA). Sequencing was performed on the Illumina 453 
MiSeq and HiSeq. Sample processing and metadata were tracked within our laboratory information 454 
management system.79,80 Sequencing reads were processed by a dedicated bioinformatics pipeline 455 
(VISPA2).80 Briefly, paired sequence reads were filtered for raw reads quality, then cleaned by vector 456 
genome, and the resulting cellular genomic sequence mapped on the human genome (version hg19), 457 
and the nearest RefSeq gene assigned to each unambiguously mapped IS. Clonal abundance for each 458 
IS was estimated using the R package sonicLength,81 where the number of genomes with the same 459 
integration site is calculated by counting the number of fragments with different sizes generated by 460 
sonication belonging to each individual IS. Within each group, IS shared between different time 461 
points of the same transduction were counted once. The relative abundance of each clone was then 462 
calculated as the percentage of genomes with a specific integration site over the total genomes. 463 
Common Insertion Sites (CIS) were identified through the Grubbs test for outliers.82 Enrichment 464 
analysis for ontological classes among the targeted genes by vector IS was performed by the Genomic 465 
Regions Enrichment of Annotations Tool (G.R.E.A.T.).83 466 
Animal procedures 467 
Animal studies were approved by the Animal Care and Use Committee at UPO (Italian Health 468 
Ministry Authorization n. 492/2016-PR, No. DBO64.5). NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (Jackson 469 
stock No 005557) mice with hemophilic phenotype (NSG-HA) were previously generated and 470 
maintained in our laboratory.22  Eight-10 week old animals were used for cell transplantation studies. 471 










the Animal Care Committee at the University of British Columbia (Vancouver, British Columbia, 473 
Canada) in accordance with the Canadian Council on Animal Care Guide to the Care and Use of 474 
Experimental Animals. 475 
BOEC transplantation 476 
 For cell transplantation with beads, 5x106 FVIII-transduced healthy or HA BOECs were mixed with 477 
Cytodex®3 microcarrier beads (GE Healthcare Life Sciences) and intraperitoneally delivered in NSG-478 
HA mice as previously described.23 For Cell Pouch™ implantation, female NSG and NSG-HA 479 
animals were anesthetized and surgically implanted with a Cell Pouch™ in the subcutaneous space 480 
of the lower abdomen 4 weeks before cell transplantation, allowing incorporation with vascularized 481 
tissue and forming fully developed tissue chambers suitable for cell transplantation upon removal of 482 
a space holding plug. LV-VEC.hBDD-FVIII BOECs were cultured for 3 days post-thawing and 483 
finally transplanted into the Cell Pouch™. Mice received either a dose of viable BOECs (2-20×106) 484 
or remained untreated. All animals received a prophylactic dose (2-4 IU) of recombinant human FVIII 485 
by tail vein injection prior to surgical procedures.  486 
FVIII activity 487 
aPTT assay was performed on plasma samples of transplanted mice to assess FVIII activity. Standard 488 
curves were generated by serial dilution of recombinant human BDD-FVIII (ReFacto) in hemophilic 489 
mouse plasma. Analyses were performed using a Coatron® M4 coagulometer (TECO Medical 490 
Instruments) and TEClot APTT-S kit reagents (TECO Medical Instruments).  491 
Bleeding assay 492 
A bleeding assay was performed on anesthetized mice. The distal portion of the tail was cut at a 493 
diameter of 2-2.5 mm. Tails were placed in a conical tube containing 14 ml of 37C pre-warmed 494 
saline. Blood was collected for 10 min and, following centrifugation, resuspended in red blood lysis 495 
buffer (155 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA). The absorbance of the samples was 496 










was performed by Sernova, as previously described,84,85 at the end of the experimental period, 4 498 
months post-transplantation. In brief, mice were anesthetized, and tail tips were placed in a guide, 499 
ensuring the same diameter of 1-mm, and severed (~ a distal 10-mm segment) for each animal. The 500 
tail was immediately immersed in pre-warmed saline at 37C. Bleeding was carried out for a 501 
maximum of 20 min, after which animals were euthanized as per approved animal use protocol 502 
(AUP). Blood loss was evaluated by determining hemoglobin concentration by lysing collected red 503 
blood cells (ACK Lysing Buffer, Gibco™), and the absorbance measured at 550 nm on a Synergy™ 504 
Mx (BioTeck) spectrophotometer. Results were analyzed by comparing the amount of blood loss 505 
obtained from treated NSG-HA mice with control mice (untreated NSG-HA and NSG mice). 506 
Statistical analysis 507 
Data were expressed as means ± standard deviation (SD) or means ± standard error mean (SEM).  508 
Statistical significance was analyzed using Student’s t test with two-tailed distribution, assuming 509 
equal standard deviation distribution, two-way analysis of variance (ANOVA) with Bonferroni post-510 
hoc test or Tukey’s multiple comparison post hoc tests in GraphPad Prism 6 (GraphPad Software). 511 
Statistical analyses involving IS were performed with the R software (r- project.org). Differences 512 
were considered statistically significant when P values < 0.05.  513 
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 801 
 Figure legends 802 
 Figure 1. Healthy and HA BOEC isolation, LV transduction, and in vitro FVIII detection. (A) 803 
Light microscope pictures of cultured healthy and HA BOECs at passage 3. (B) Representative RT-804 
PCR analysis for the expression of endothelial markers. HUVECs and fibroblasts were used as 805 
positive and negative control, respectively. (C) RT-PCR for endothelial markers specific for blood 806 
endothelial cells (BECs). iPSC-derived ECs and fibroblasts were used as positive and negative 807 
control, respectively. (D) Representative histograms of healthy non-transduced (black line) and LV-808 
VEC.hBDD-FVIII transduced healthy BOECs (red line), showing endothelial marker expression and 809 
absence of hematopoietic markers. The filled-up histograms represent unstained BOECs. (E) 810 
Representative histograms of HA non-transduced (black line) and LV-VEC.hBDD-FVIII transduced 811 
HA BOECs (red line) showing endothelial marker expression and absence of hematopoietic markers. 812 
The filled-up histograms represent unstained BOECs. (F) Matrigel assay confirming tubule formation 813 
of transduced BOECs. (G) RT-PCR, using primers specific for the exogenous F8 in non-transduced 814 
and LV-VEC.hBDD-FVIII BOECs. Unrelated transduced cells and fibroblast were used as positive 815 
and negative control respectively. (H) FVIII intracytoplasmic staining on non-transduced (black line) 816 
or transduced healthy BOECs (red line).  The filled-up histogram represents unstained BOECs. (I) 817 
FVIII intracytoplasmic staining on non-transduced (Black line) or transduced HA BOECs (Red line). 818 
The filled-up histogram represents unstained BOECs. (J) FVIII detection by immunofluorescence: 819 
blue: DAPI, red: anti-FVIII. Data are expressed as mean ± SD and are representative of four 820 
independent experiments. 821 
Figure 2. Intraperitoneal implantation of BOECs with Cytodex micro-carrier beads. (A) 822 
Kinetics of the percentage of FVIII activity measured by aPTT assay in the plasma of transplanted 823 










FVIII and LV-VEC.GFP. Data are expressed as mean ± SD and are representative of two independent 825 
experiments using BOECs from two healthy donors (n = 7 mice), and four independent experiments 826 
using HA BOECs from four patients (n = 23 mice). (B) Blood loss evaluation on NSG-HA mice 827 
between week 7 and 10 (n = 4) after cell transplantation. (C) FVIII concentration in plasma of mice 828 
transplanted with transduced or non-transduced BOECs at week 16. Data are expressed as mean ± 829 
SD, (P < 0.0001 ***, P < 0.001 **) (D) Representative immunofluorescence on beads showing cells 830 
co-expressing GFP and CD31. 831 
Figure 3. Large-scale expansion of HA patient derived BOECs. (A) Light microscope pictures of 832 
transduced HA BOECs pre- and post-expansion. (B) Cell size, cell density, culture time, and 833 
population doubling level during pre- and post- large-scale expansion. (C) Endothelial marker 834 
expression pre- and post- large-scale expansion expressed as stained cells vs cells with secondary 835 
isotype controls. (D) Tubulogenic assay to assess the functionality of transduced HA BOECs after 836 
pre- and post-large-scale expansion. (E) Kinetics of the percentage of FVIII activity measured by 837 
aPTT assay in plasma of transplanted NSG-HA mice. Data are expressed as mean ± SD and are 838 
representative of two independent experiments (n = 7). 839 
Figure 4. Pathological assessment after transplantation of LV-VEC.hBDD-FVIII HA BOECs 840 
into the Cell Pouch™ device. (A) Sernova Cell Pouches™ were removed at 4, 8, or 12 weeks and 841 
stained by H&E and Masson’s Trichrome for blinded histopathological analysis. Histology scores 842 
and representative images at 12 weeks post- transplant with 10×106 LV-VEC.hBDD-FVIII BOECs 843 
(animal groups n = 2-3). (B) Quantification of H&E and Masson’s Trichrome for blinded 844 
histopathological analysis. 845 
Figure 5. Bleeding phenotype and cell survival of LV-VEC.hBDD-FVIII HA BOECs after 846 
implantation in the Cell Pouch™ device. (A) Bleeding assay on mice transplanted with 10×106 or 847 
20×106 HA and LV-VEC.hBDD-FVIII BOECs, or left untreated (n = 3-6, mean ± SEM, **P < 0.05, 848 
ns: not significant). NSG mice were used as control for bleeding assay. (B) The transplanted Cell 849 










performed to detect cell survival within the mouse tissue by human cell staining (HLA-ABC) and 851 
blood vessel formation through staining with cross-reacting human/mouse von Willebrand Factor 852 
(vWF) antibody. The images shown are representative of two transplant groups (10×106 n = 5; 20×106 853 
n = 12). (C) Quantification of HLA-ABC and blood vessel formation from blinded histopathological 854 
assessment. 855 
Figure 6. Genome wide distribution of lentiviral vector IS. (A) The pink track represents the 856 
density distribution of genes (RefSeq annotation, hg19 genome). The green tracks are the density 857 
distributions of all the IS retrieved in the HA transduced with LV-VEC.GFP and Healthy transduced 858 
with LV-VEC.GFP groups. The blue tracks are the density distributions of all the IS retrieved in the 859 
LV-VEC.hBDD-FVIII HA BOECs and LV-VEC.hBDD-FVIII Healthy BOECs groups. (B) 860 
Distribution of IS of the 4 groups along the whole human genome and with respect to gene 861 
transcription start site (TSS). 862 
Figure 7. Box plot representation of clonal abundance. For each sample, the abundance values for 863 
each clone are represented as dots. Clones over 10% are presented as dots labeled with the closest 864 
gene symbol (RefSeq hg19). 865 
Figure 8. Clonal diversity comparison. (A) Shannon diversity index for each transduced cell 866 

































































eTOC Synopsis  
BOECs from HA patients and healthy donors were isolated, expanded, and LV-FVIII-transduced 
under GMP-like procedures. Amelioration of bleeding phenotype in a preclinical mouse model was 
reached by implantation of FVIII gene corrected hemophilic BOECs injected in a pre-vascularized 
Cell PouchTM reaching a long-term engraftment with a safe genomic integration profile. 
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